Kiniksa Pharmaceuticals
KNSA
127 hedge funds and large institutions have $448M invested in Kiniksa Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 49 increasing their positions, 43 reducing their positions, and 23 closing their positions.
33% more call options, than puts
Call options by funds: $4.47M | Put options by funds: $3.37M
32% more capital invested
Capital invested by funds: $340M → $448M (+$108M)
14% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 43
0.47% less ownership
Funds ownership: 91.39% → 90.92% (-0.47%)
4% less funds holding
Funds holding: 132 → 127 (-5)
22% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$9.43M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$8.06M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$6.95M |
| 4 |
GC
GMT Capital
Atlanta,
Georgia
|
+$4.01M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$3.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$6.44M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.85M |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$4.27M |
| 4 |
Millennium Management
New York
|
-$3.93M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$3.16M |
KNSA Hedge Fund Activity: Q2 2023 in Review
127 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q2 2023, worth a combined $448M — up 32% from $340M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of KNSA and 18 opened new positions — a net loss of 5 holders — while 43 trimmed existing stakes and 49 added.
The largest buyer was Fairmount Funds Management, opening a new position worth an estimated $9.43M. The largest seller was Marshall Wace, cutting an estimated $6.44M.
- 127 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q2 2023, down from 132 in Q1 2023.
- Funds reported $448M of Kiniksa Pharmaceuticals stock for Q2 2023, up 32% quarter-over-quarter.
- 18 funds opened new Kiniksa Pharmaceuticals positions in Q2 2023 and 23 closed out, a net change of -5 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q2 2023 was Fairmount Funds Management, an estimated $9.43M added.
- The largest Kiniksa Pharmaceuticals seller in Q2 2023 was Marshall Wace, an estimated $6.44M sold.
Based on aggregated 13F filings for Q2 2023.